⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128856 | 0.88 | HPGD (0.33) | — | |
| SCHEMBL367995 | 0.83 | — | — | |
| SCHEMBL1147443 | 0.75 | — | — | |
| SCHEMBL5199456 | 0.72 | VHL (0.50) | — | |
| SCHEMBL2798014 | 0.71 | — | — | |
| SCHEMBL132599 | 0.71 | HPGD (0.33) | — | |
| SCHEMBL909737 | 0.69 | HDAC1 (0.47) | — | |
| SCHEMBL129203 | 0.68 | TNKS2 (0.30) | — | |
| SCHEMBL128823 | 0.68 | TNKS2 (0.30) | — | |
| SCHEMBL1012871 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | claimed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | claimed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | claimed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | claimed |
| EP-0901469-B1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | UNIV MONASH (AU) | 2003-08-27 | — | — | EP | claimed |
| US-6232314-B1 | SUCH AS 1-(2-(4-CHLOROPHENYL)-2-HYDROXY)ETHYL-4-(3,5-BIS(1,1-DIMETHYLETHYL)-4 -HYDROXYPHENYL)METHYLPIPERAZINE; USED TO TREAT STROKE, CARDIAC ARREST, ISCHAEMIA, HYPOXIA, HYPOGLYCAEMIA, EPILEPSY, AND AMYOTROPHIC LATERAL SCLEROSIS | MONASH UNIVERSITY (AU) | 2001-05-15 | — | — | US | claimed |
| EP-0901469-A4 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | UNIV MONASH (AU) | 2000-11-15 | — | — | EP | claimed |
| EP-0901469-A1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | MONASH UNIVERSITY (AU) | 1999-03-17 | — | — | EP | claimed |
| WO-1997043259-A1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | MONASH UNIVERSITY (AU) | 1997-11-20 | — | — | WO | claimed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-118338907-A | Lipid Nanoparticle (LNP) compositions and methods of using the same | 宾夕法尼亚大学董事会 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0269859-A2 | Pyrazolotriazine compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |